NASDAQ:APLT - Applied Therapeutics Stock Price, Forecast & News

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APLT stock has increased by 2.9% and is now trading at $30.44. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Therapeutics.

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, June 19th 2020. View our earnings forecast for Applied Therapeutics.

Applied Therapeutics (NASDAQ:APLT) announced its earnings results on Wednesday, November, 13th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.14. View Applied Therapeutics' earnings history.

5 equities research analysts have issued 12-month price targets for Applied Therapeutics' shares. Their forecasts range from $43.00 to $65.00. On average, they expect Applied Therapeutics' share price to reach $54.00 in the next year. This suggests a possible upside of 77.4% from the stock's current price. View analysts' price targets for Applied Therapeutics.

News coverage about APLT stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Applied Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutApplied Therapeutics.

Applied Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 415,400 shares, an increase of 25.4% from the February 13th total of 331,300 shares. Based on an average daily volume of 240,400 shares, the short-interest ratio is presently 1.7 days. Approximately 3.4% of the shares of the company are short sold. View Applied Therapeutics' Current Options Chain.

Some companies that are related to Applied Therapeutics include Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), Allakos (ALLK), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), ArQule (ARQL), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Alkermes (ALKS) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Boeing (BA), Walt Disney (DIS), Home Depot (HD), Square (SQ), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP) and eHealth (EHTH).

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Applied Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (3.41%), FMR LLC (1.30%), Artisan Partners Limited Partnership (0.85%), Sofinnova Investments Inc. (0.62%), Oppenheimer & Co. Inc. (0.43%) and State Street Corp (0.39%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends for Applied Therapeutics.

APLT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, and Sofinnova Investments Inc.. View insider buying and selling activity for Applied Therapeutics.

APLT stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Emerald Mutual Fund Advisers Trust, Oppenheimer & Co. Inc., State Street Corp, Driehaus Capital Management LLC, Geode Capital Management LLC, Barclays PLC, and Emerald Advisers LLC. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter. View insider buying and selling activity for Applied Therapeutics.

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APLT stock can currently be purchased for approximately $30.44.

Applied Therapeutics has a market capitalization of $668.77 million. Applied Therapeutics employs 4 workers across the globe. View additional information about Applied Therapeutics.

The official website for Applied Therapeutics is http://www.appliedtherapeutics.com/.

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]